Fáilte chuig an Institiúid um Leigheas Athghiniúnach
Welcome to the Regenerative Medicine Institute (REMEDI®)

Dr. Mary Murphy

+353 91-495206
Chondrogenic differentiation of stem cells derived from the aorta of an atherosclerotic mouse

Lecturer in Regenerative Medicine & Director of Toxicology, REMEDI

The Biology, Mechanism of action and Use of adult stem cells for tissue regeneration in osteoarthritis.

Researcher in

Research Project Area: 

In the Orthobiologics Group, research focuses on investigating the mechanisms whereby stem cells can prevent development of OA and how they can be used to repair damaged, osteoarthritic cartilage or promote integration of metal implants currently used for joint replacement. Specific projects will investigate:
a) mechanisms to understand how stem cells can act “trophically” to modulate the immune response and/or mobilise host cells for tissue protection in the joint
b) strategies to promote cartilage repair by targeting stem cells to early osteoarthritic tissue or use novel biomaterial formulations to treat focal cartilage lesions and
c) ways to promote recruitment of endogenous osteoprogenitors for improved metal implant integration with host tissue to extend the lifespan and success of joint replacements.

The biology, mechanism of action and the use of adult stem cells for tissue regeneration in orthopaedic applications with a specific emphasis in cartilage repair and osteoarthritis. This research focuses on the isolation, characterization and differentiation of mesenchymal stem cells, the effects of ageing and disease on stem cells, and the development of pertinent models and therapeutic modalities for mesenchymal stem cells in tissue regeneration.

Biology of vascular derived stem cells in atherosclerosis

Cardiomyogenic differentiation of adult stem cells: effect of electroactive particles (collaboration with Valerie Barron, NCBES)

Positions Held: 

2006-present: Lecturer in Regenerative Medicine, Dept. of Medicine, NUI, Galway

2004-present: Principal Investigator, REMEDI Orthobiology Group & Director of Toxicology, REMEDI, NUIG

2001-2004: Senior Manager, Arthritis Research Osiris Therapeutics Inc., Baltimore, MD, USA 

1999-2001: Manager, Arthritis Research

1995-1999: Research Scientist, Cartilage Res. and Analytical Biochemistry

1991-1994: Postdoctoral fellow Department of Obstetrics and Gynaecology, University of South Florida, Tampa, Florida, USA Etiology of smooth muscle cell tumours

1990-1991: Postdoctoral fellow Department of Ophthalmology, University of South Florida, Tampa, Florida, USA The early events in the formation of connective tissue during wound repair

Research fellow Department of Medicine, University College Cork, Ireland Renin-angiotensin system in diabetes

1986-1988: Postdoctoral fellow Dept of Food Chemistry, University College Cork, Ireland Isolation and characterization of milk proteins

1983-1986: Research Biochemist Research Biochemist, Clinical Diagnostics Division, Flemming GmbH, Co. Clare, Ireland
Development of clinical diagnostic reagents


Awards & Honours: 

 Current Research Funding

EU FP7-NMP-2009-2.3-1: GAMBA: Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis; Sept 2010 - Aug 2013; €,382K (PI)).

EU FP7-HEALTH-2007-B: PurStem: Utilisation of the mesenchymal stem cell receptome for rational development of uniform, serum-free culture conditions and tools for cell characterization; Nov 2008 – Oct 2011; €285K (WP leader).

IDA - Smith & Nephew / REMEDI R&D collaboration: Stem Cell-based Cartilage Repair; Oct 2009 – Sept 2011; €148K (co-PI).

IRCSET: Stem cells in Vascular Calcification associated with Atherosclerosis; Oct 08 – Sept 2011; €70,000 (PI).

Selected Publications: 

Invited/Preer Reviewed Publications

Coleman CM, Curtin C, Barry FP, O'Flatharta C, Murphy JM. Mesenchymal stem cells and osteoarthritis: remedy or accomplice? Hum Gene Ther. 2010 Oct;21(10):1239-50.


Little CB, Smith MM, Cake MA, Read RA, Murphy MJ, Barry FP. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in sheep and goats. Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S80-92.

Calderon L, Collin E, Velasco-Bayon D, Murphy M, O'Halloran D, Pandit A. Type II collagen-hyaluronan hydrogel--a step towards a scaffold for intervertebral disc tissue engineering. Eur Cell Mater. 2010 Sep 6;20:134-48.

Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, Miller N, Hennessy E, Dockery P, Barry FP, O'Brien T, Kerin MJ. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat. 2010 Nov;124(2):317-26. Epub 2010 Jan 20.

O'Shea CA, Hynes SO, Shaw G, Coen BA, Hynes AC, McMahon J, Murphy M, Barry F, O'Brien T. Bolus delivery of mesenchymal stem cells to injured vasculature in the rabbit carotid artery produces a dysfunctional endothelium. Tissue Eng Part A. 2010 May;16(5):1657-65.

Hoare M, Greiser U, Schu S, Mashayekhi K, Aydogan E, Murphy M, Barry F, Ritter T, O'Brien T. Enhanced lipoplex-mediated gene expression in mesenchymal stem cells using reiterated nuclear localization sequence peptides. J Gene Med. 2010 Feb;12(2):207-18.

O'Cearbhaill ED, Murphy M, Barry F, McHugh PE, Barron V. Behavior of human mesenchymal stem cells in fibrin-based vascular tissue engineering constructs. Ann Biomed Eng. 2010 Mar;38(3):649-57

Mooney E, Dockery P, Greiser U, Murphy M*, Barron V*. Carbon Nanotubes and Mesenchymal Stem Cells: Biocompatibility, Proliferation and Differentiation. Nano Lett. 2008 Jul 12. [Epub ahead of print]

Dwyer, RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Murphy JM, Barry FP, O’Brien T and Kerin MJ. Monocyte Chemotactic Protein-1 (MCP-1) secreted by primary breast tumors stimulates migration of Mesenchymal Stem Cells (MSCs). Clinical Cancer Research (2007) 13 (17): 5020-5027.

Barry FP, Murphy JM, English K, Mahon BP (2005). Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev 14:252-65.

Barry FP, Murphy JM (2004). Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 36:568-84.

Murphy JM, Fink DJ, Hunziker EB, Barry FP (2003). Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 48:3464-74.

Murphy JM, Dixon K, Beck S Fabian DF, Feldman A, Barry FP (2002). Reduced chondrogenic and adipogenic activity of MSCs from patients with advanced osteoarthritis. Arthritis Rheum 46:704-713.

Barry F, Boynton R, Murphy M and Zaia J (2001). The SH-3 and SH-4 Antibodies Recognize Distinct Epitopes on CD73 from Human Mesenchymal Stem Cells. Biochem. Biophys. Res. Commun. 289:519-24

Barry F, Boynton RE, Liu B and Murphy JM (2001). Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp. Cell Res. 268:189-200

Barry FP, Boynton RE, Haynesworth S, Murphy JM and Zaia J (1999). The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun. 265:134-139.

Murphy JM, Heinegård D, McIntosh A, Sterchi D and Barry FP (1999). Distribution of cartilage molecules in the developing mouse joint: articular chondrocytes constitute a unique sub-set of cells. Matrix Biol. 18:487-497.

MacKay AM, Beck SC, Murphy JM, Barry FP, Chichester CO and Pittenger MF (1998). Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng. 4:415-428.

Professional and Personal Interests: 


• Orthopaedic Research Society
• Osteoarthritis Research Society International
• International Society for Cell Therapy
• International Society for Stem Cell Research
• European Society of Gene Therapy
• British Society for Matrix Biology
• Irish Society for Gene & Cell Therapy

Search PubMed for Papers by Dr. Mary Murphy >>